Illuminaの価格/簿価
Illuminaの価格/簿価は何ですか。
Illumina, Inc.の価格/簿価は0.02です。
価格/簿価の定義は何ですか。
株価純資産倍率は、会社の株価と1株当たりの簿価との比率を表します。
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
LSEのセクタMiscellaneousにおける価格/簿価の企業と比べるIllumina
Illuminaは何をしますか。
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
Illuminaと類似の価格/簿価
- Golden Prospect Precious Metalsの価格/簿価は0.02です。
- Denbury Resourcesの価格/簿価は0.02です。
- Surgutneftegas PJSCの価格/簿価は0.02です。
- Under Armourの価格/簿価は0.02です。
- Kinder Morganの価格/簿価は0.02です。
- Retrophinの価格/簿価は0.02です。
- Illuminaの価格/簿価は0.02です。
- Consolidated Edisonの価格/簿価は0.02です。
- CenterPointの価格/簿価は0.02です。
- Tattooed Chefの価格/簿価は0.02です。
- Lassila & Tikanoja Oyjの価格/簿価は0.02です。
- Fifth Third Bancorpの価格/簿価は0.02です。
- Thredの価格/簿価は0.02です。